Please see full Important Safety Information (ISI) below & at https://www.enhertuhcp.com/en/#isi
Select ISI
Selected Information Regarding Warnings and Precautions
ENHERTU is associated with a number of serious, potentially fatal, Warnings and Precautions, including Interstitial Lung Disease/Pneumonitis, Neutropenia, Left Ventricular Dysfunction, Embryo-Fetal Toxicity. Please see Important Safety Information.
For complete list of ENHERTU Indications, visit www.enhertuhcp.com.
For US HCPs only. ENHERTU® is a Daiichi Sankyo & AstraZeneca brand & is not associated with any individual users. To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.
Company Details
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://enhertuhcp.com/en/
Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki) Hcp Questions
Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki) Hcp's website is http://enhertuhcp.com/en/
Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki) Hcp's LinkedIn profile is https://www.linkedin.com/company/enhertu-hcp
Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki) Hcp's industry is
Pharmaceutical Manufacturing
Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki) Hcp's top competitors are
Cimzia® (Certolizumab Pegol) Hcp,
Benlysta (Belimumab),
Astrazeneca,
Tezspire® (Tezepelumab-Ekko) Hcp,
Tagrisso® (Osimertinib) Hcp,
Opdivo® (Nivolumab) Us Hcp,
Zerbaxa® (Ceftolozane And Tazobactam) Hcp,
Entyvio (Vedolizumab),
Kisqali Hcp,
Keytruda® (Pembrolizumab) Hcp.
Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki) Hcp's categories are Pharmaceutical Manufacturing
